Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on during any economic environment. This is because patients need their ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. The company has been one of the best-performing pharmaceutical giants, with its shares ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 33 trades. If we consider the specifics of each ...

Eli Lilly stock has advanced more than 200% over the past three years thanks to the company’s dominance in the weight loss drug market. Lilly may face more competitors down the road in this high ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Eli Lilly and Co. Wednesday announced plans to build four pharmaceutical manufacturing sites in the United States, significantly boosting domestic medicine production and adding around 13,000 ...

New results show Eli Lilly (LLY) and Company’s Ebglyss achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years. These findings from the ADjoin ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch.

That negative investor reaction was directed at companies involved in the white-hot weight loss drug segment of the market (Eli Lilly is the pharmaceutical giant behind a popular one, Zepbound).

Eli Lilly LLY-0.69%decrease; red down pointing triangle is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...